Axsome Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Axsome Therapeutics, Inc. on July 5, 2017. The filing reports the appointment of a new Chief Financial Officer and related compensatory arrangements. The company is identified as an emerging growth company.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The primary material change is the appointment of John Golubieski as Chief Financial Officer, effective August 4, 2017. He will assume the roles of principal financial officer and principal accounting officer from Constance Ames, Vice President, Finance.
Compensation and Management Commentary
Mr. Golubieski's compensation package includes the following terms:
- Base Salary: $325,000 annually.
- Target Bonus: 40% of annual base salary, prorated based on the effective date.
- Sign-on Bonus: $50,000, subject to full repayment if he voluntarily leaves within one year of the effective date.
- Equity Grant: 132,000 stock options under the 2015 Omnibus Incentive Plan. The exercise price equals the fair market value on the grant date. Vesting occurs over four years: 25% on the first anniversary, with the remaining 75% vesting in equal quarterly increments thereafter.
- Severance: Eligible for 6 months of base salary if terminated without cause within 12 months following a change in control, contingent upon a separation and release agreement.
Mr. Golubieski brings prior experience as CFO of Osmotica Holdings, LLC, Lantheus Medical Imaging Inc., and Fougera Pharmaceuticals, Inc., as well as senior roles at King Pharmaceuticals and Bristol-Myers Squibb.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 132,000 stock options granted to Mr. Golubieski.
- Confirm the transition timeline for Constance Ames stepping down as principal financial and accounting officer.
- Review the full Offer Letter (to be filed as an exhibit in the next periodic report) for additional terms and conditions not summarized here.
- Monitor future filings for any impact on the company's cash burn rate due to the new executive compensation structure.